Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 1,171 shares, an increase of 114.5% from the May 14th total of 546 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 2 shares, the days-to-cover ratio is currently 585.5 days.
Basilea Pharmaceutica Stock Performance
Shares of OTCMKTS:BPMUF opened at $60.28 on Friday. The business’s fifty day moving average price is $67.58 and its two-hundred day moving average price is $67.81. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. Basilea Pharmaceutica has a one year low of $59.29 and a one year high of $74.00.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
